A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency

References

• VollmersHPBrändleinSNatural antibodies and cancerN Biotechnol200925529429819442595
   PubMed Web of Science ®Google Scholar
• ChanOTMadaioMPShlomchikMJB cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunityJ Immunol199916373592359610490951
   PubMed Web of Science ®Google Scholar
• XuHHeXSunJShiDZhuYZhangXThe expression of B-cell activating factor belonging to tumor necrosis factor super family (BAFF) significantly correlated with C4D in kidney allograft rejectionTransplant Proc200941111211619249491
   PubMed Web of Science ®Google Scholar
• CutlerCMiklosDKimHTRituximab for steroid-refractory chronic graft-versus-host diseaseBlood2006108275676216551963
   PubMed Web of Science ®Google Scholar
• MartinBCraigPGrattanCLow-grade B-cell proliferation progressing to high-grade B-cell lymphomaAm J Dermatopathol200931657858119590416
   PubMed Web of Science ®Google Scholar
• DefoicheJDebacqCAsquithBReduction of B cell turnover in chronic lymphocytic leukemiaBr J Haematol2008143224024718710389
   PubMed Web of Science ®Google Scholar
• MaloneyDGGrillo-LópezAJWhiteCAIDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphomaBlood1997906218821959310469
   PubMed Web of Science ®Google Scholar
• WinklerUJensenMManzkeOSchulzHDiehlVEngertACytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)Blood19999472217222410498591
   PubMed Web of Science ®Google Scholar
• PersJODevauchelleVDaridonCBAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximabtreated patients with Sjögren’s syndromeArthritis Rheum20075651464147717469105
   PubMed Web of Science ®Google Scholar
• GarrettHEJrGroshartKDuvall-SeamanDCombsDSuggsRTreatment of humoral rejection with rituximabAnn Thorac Surg20027441240124212400781
   PubMed Web of Science ®Google Scholar
• ChesonBBexxar (Corixa/GlaxoSmithKline)Curr Opin Investig Drugs200231165170
   PubMedGoogle Scholar
• GenoveseMCKaineJLLowensteinMBOcrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging studyArthritis Rheum20085892652266118759293
   PubMed Web of Science ®Google Scholar
• MorschhauserFLeonardJPFayadLHumanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II resultsJ Clin Oncol200927203346335319451441
   PubMed Web of Science ®Google Scholar
• HagenbeekAGadebergOJohnsonPFirst clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialBlood2008111125486549518390837
   PubMed Web of Science ®Google Scholar
• StolzCSchulerMMolecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumventionLeuk Lymphoma200950687388519373595
   PubMed Web of Science ®Google Scholar
• PawluczkowyczAWBeurskensFJBinding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTXJ Immunol2009183174975819535640
   PubMed Web of Science ®Google Scholar
• WeitzmanJBetancurMBoisselLRabinowitzAPKleinAKlingemannHVariable Contribution of Monoclonal Antibodies to ADCC in patients with chronic lymphocytic leukemiaLeuk Lymphoma20095081361136819562616
   PubMed Web of Science ®Google Scholar
• GolayJZaffaroniLVaccariTBiologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysisBlood200095123900390810845926
   PubMed Web of Science ®Google Scholar
• GlennieMJFrenchRRCraggMSTaylorRPMechanisms of killing by anti-CD20 monoclonal antibodiesMol Immunol200744163823383717768100
   PubMed Web of Science ®Google Scholar
• CvetkovićRSPerryCMSpotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemiaBioDrugs200620425325716831024
   PubMed Web of Science ®Google Scholar
• BolandABagustAHockenhullJDavisHChuPDicksonRRituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphomaHealth Technol Assess200913Suppl 24148
   Google Scholar
• TreonSPMitsiadesCMitsiadesNTumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignanciesJ Immunother2001243263271
   Web of Science ®Google Scholar
• DimopoulosMAKastritisERoussouMRituximab-based treatments in Waldenström‘s macroglobulinemiaClin Lymphoma Myeloma200991596119362975
   PubMedGoogle Scholar
• SonetABoslyARituximab and chemotherapy in diffuse large B-cell lymphomaExpert Rev Anticancer Ther20099671972619496708
   PubMed Web of Science ®Google Scholar
• ChristianBALinTSAntibody therapy for chronic lymphocytic leukemiaSemin Hematol20084529510318381104
   PubMed Web of Science ®Google Scholar
• AueGLindorferMABeumPVFractionated subcutaneous Rituximab is well tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemiaHaematologica201095932933219679883
   PubMed Web of Science ®Google Scholar
• WilliamsMEDensmoreJJPawluczkowyczAWThrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemiaJ Immunol2006177107435744317082663
   PubMed Web of Science ®Google Scholar
• GriffinTCWeitzmanSWeinsteinHChildren‘s Oncology Group. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology GroupPediatr Blood Cancer200952217718118816698
   PubMed Web of Science ®Google Scholar
• SalehMNGutheilJMooreMA pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopeniaSemin Oncol2000276 Suppl 129910311226008
   PubMed Web of Science ®Google Scholar
• AggarwalACatlettJPRituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpuraSouth Med J200295101209121212425512
   PubMed Web of Science ®Google Scholar
• DierickxDVerhoefGVan HoofARituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric studyJ Intern Med2009266548449119549092
   PubMed Web of Science ®Google Scholar
• Devauchelle-PensecVPennecYMorvanJImprovement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20)Arthritis Rheum200757231031717330280
   PubMed Web of Science ®Google Scholar
• DingCFooteSJonesGB-cell-targeted therapy for systemic lupus erythematosus: an updateBioDrugs200822423924918611066
   PubMed Web of Science ®Google Scholar
• WeideRHeymannsJPandorfAKöpplerHSuccessful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapyLupus2003121077978214596428
   PubMed Web of Science ®Google Scholar
• LeandroMJCambridgeGEdwardsJCEhrensteinMRIsenbergDAB-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patientsRheumatology (Oxford)200544121542154516188950
   PubMed Web of Science ®Google Scholar
• MandersonAPBottoMWalportMJThe role of complement in the development of systemic lupus erythematosusAnnu Rev Immunol20042243145615032584
   PubMed Web of Science ®Google Scholar
• RobakTOfatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disordersCurr Opin Mol Ther200810329430918535937
   PubMedGoogle Scholar
• RoccatelloDBaldovinoSAlpaMEffects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvementClin Exp Rheumatol2008263 Suppl 49S67S7118799057
   PubMed Web of Science ®Google Scholar
• BerentsenSTjønnfjordGEBrudevoldRFavorable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin diseaseBr J Haematol20011151798311722415
   PubMed Web of Science ®Google Scholar
• FieldJJFenskeTSBlinderMARituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapyHaemophilia2007131465017212724
   PubMed Web of Science ®Google Scholar
• CollinsMNavaneethanSDChungMRituximab treatment of fibrillary glomerulonephritisAm J Kidney Dis20085261158116218823685
   PubMed Web of Science ®Google Scholar
• ZambrunoGBorradoriLRituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletionJ Invest Dermatol2008128122745274718997839
   PubMed Web of Science ®Google Scholar
• CooperMAWillinghamDLBrownDEFrenchARShihFFWhiteAJRituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patientsArthritis Rheum20075693107311117763414
   PubMed Web of Science ®Google Scholar
• DassSVitalEMEmeryPDevelopment of psoriasis after B cell depletion with rituximabArthritis Rheum20075682715271817665440
   PubMed Web of Science ®Google Scholar
• MielkeFSchneider-ObermeyerJDörnerTOnset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphomaAnn Rheum Dis20086771056105718556453
   PubMed Web of Science ®Google Scholar
• VenetzJPPascualMNew treatments for acute humoral rejection of kidney allograftsExpert Opin Investig Drugs2007165625633
   PubMed Web of Science ®Google Scholar
• BillingHRiegerSOvensJSuccessful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipientsTransplantation20088691214122119005402
   PubMed Web of Science ®Google Scholar
• KesslerLParissiadisABayleFOn behalf of the GRAGIL Study Group. Evidence for Humoral Rejection of a Pancreatic Islet Graft and Rescue with Rituximab and IV Immunoglobulin TherapyAm J Transplant2009981961196619522877
   PubMed Web of Science ®Google Scholar
• TeshimaTNagafujiKHenzanHRituximab for the treatment of corticosteroid-refractory chronic graft-versus-host diseaseInt J Hematol200990225326019543951
   PubMed Web of Science ®Google Scholar
• BeumPVLindorferMABeurskensFComplement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysisJ Immunol2008181182283218566448
   PubMed Web of Science ®Google Scholar
• van der KolkLEGrillo-LópezAJBaarsJWHackCEvan OersMHComplement activation plays a key role in the side-effects of rituximab treatmentBr J Haematol2001115480781111843813
   PubMed Web of Science ®Google Scholar
• KlepfishAGillesLIoannisKEliezerRAmiSEnhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions and clinical results in refractory CLLAnn N Y Acad Sci2009117386587319758239
   PubMed Web of Science ®Google Scholar
• KennedyADBeumPVSolgaMDRituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemiaJ Immunol200417253280328814978136
   PubMed Web of Science ®Google Scholar
• ManchesOLuiGChaperotLIn vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomasBlood2003101394995412393572
   PubMed Web of Science ®Google Scholar
• RacilaELinkBKWengWKA polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphomaClin Cancer Res200814206697670318927313
   PubMed Web of Science ®Google Scholar
• CohenAMShinitzkyMModulation of complement lysis of human erythrocytes by the membrane lipid viscosityVox Sang198243123277113115
   PubMed Web of Science ®Google Scholar
• SemacIPalombaCKulangaraKAnti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cellsCancer Res200363253454012543813
   PubMed Web of Science ®Google Scholar
• WuJEdbergJCRedechaPBA novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune diseaseJ Clin Invest19971005105910709276722
   PubMed Web of Science ®Google Scholar
• CartronGDacheuxLSallesGTherapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa geneBlood200299375475811806974
   PubMed Web of Science ®Google Scholar
• JanasEPriestRWildeJIWhiteJHMalhotraRRituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosisClin Exp Immunol2005139343944615730389
   PubMed Web of Science ®Google Scholar
• PetrieRJDeansJPColocalization of the B cell receptor and CD20 followed by activation-dependent dissociation in distinct lipid raftsJ Immunol200216922886289112218101
   PubMed Web of Science ®Google Scholar
• PedersenIMBuhlAMKlausenPGeislerCHJurlanderJThe chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanismBlood20029941314131911830481
   PubMed Web of Science ®Google Scholar
• ChanHTHughesDFrenchRRCD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane raftsCancer Res200363175480548914500384
   PubMed Web of Science ®Google Scholar
• FeugierPVan HoofASebbanCLong-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’AdulteJ Clin Oncol200523184117412615867204
   PubMed Web of Science ®Google Scholar
• MankaïABordronARenaudineauYPurine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cellsCancer Res200868187512751918794139
   PubMed Web of Science ®Google Scholar
• MankaïABuhéVYouinouPGhediraIBerthouCBordronAImprovement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated up-regulation of CD20 expression independently of PU.1Ann N Y Acad Sci2009117372172819758221
   PubMed Web of Science ®Google Scholar
• GongQOuQYeSImportance of cellular microenvironment and circulatory dynamics in B cell immunotherapyJ Immunol2005174281782615634903
   PubMed Web of Science ®Google Scholar
• AhujaAShupeJDunnRKashgarianMKehryMRShlomchikMJDepletion of B cells in murine lupus: efficacy and resistanceJ Immunol200717953351336117709552
   PubMed Web of Science ®Google Scholar
• KimSJLeeSJChoiIYSerum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapyEur J Haematol200881317718418510703
   PubMed Web of Science ®Google Scholar
• PersJODevauchelleVDaridonCBAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren’s syndromeArthritis Rheum20075651464147717469105
   PubMed Web of Science ®Google Scholar
• BrownDARoseJKSorting of GPI-anchored proteins to glycolipid enriched membrane subdomains during transport to the apical cell surfaceCell19926835335441531449
   PubMed Web of Science ®Google Scholar
• PikeLJHanXChungKNGrossRWLipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysisBiochemistry20024162075208811827555
   PubMed Web of Science ®Google Scholar
• FridrikssonEKShipkovaPASheetsEDHolowkaDBairdBMcLaffertyFWQuantitative analysis of phospholipids in functionally important membrane domains from RBL-2H3 mast cells using tandem high-resolution mass spectrometryBiochemistry199938258056806310387050
   PubMed Web of Science ®Google Scholar
• PikeLJRafts defined: a report on the Keystone Symposium on Lipid Rafts and Cell FunctionJ Lipid Res20064771597159816645198
   PubMed Web of Science ®Google Scholar
• RajendranLSimonsKLipid rafts and membrane dynamicsJ Cell Sci2005118Pt61099110215764592
   PubMed Web of Science ®Google Scholar
• Hanzal-BayerMFHancockJFLipid rafts and membrane trafficFEBS Lett200758111209104
   Web of Science ®Google Scholar
• SohnHWTolarPPierceSKMembrane heterogeneities in the formation of B cell receptor-Lyn kinase microclusters and the immune synapseJ Cell Biol2008182236737918644892
   PubMed Web of Science ®Google Scholar
• LingwoodDSimonsKLipid rafts as a membrane-organizing principleScience20103275961465020044567
   PubMed Web of Science ®Google Scholar
• LiHAyerLMPolyakMJThe CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanismJ Biol Chem200427919198931990114976189
   PubMed Web of Science ®Google Scholar
• SetterbladNBécartSCharronDMooneyNB cell lipid rafts regulate both peptide-dependent and peptide-independent APC-T cell interactionJ Immunol200417331876188615265920
   PubMed Web of Science ®Google Scholar
• XiaMWangQZhuHLipid rafts regulate cellular CD40 receptor localization in vascular endothelial cellsBiochem Biophys Res Commun2007361376877417678876
   PubMed Web of Science ®Google Scholar
• OneyamaCHikitaTEnyaKThe lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-SrcMol Cell200830442643618498747
   PubMed Web of Science ®Google Scholar
• SpiegelSInsertion of ganglioside GM1 into rat glioma C6 cells renders them susceptible to growth inhibition by the B subunit of cholera toxinBiochim Biophys Acta198896932492562835987
   PubMed Web of Science ®Google Scholar
• FantiniJMarescaMHammacheDYahiNDelézayOGlycosphingolipid (GSL) microdomains as attachment platforms for host pathogens and their toxins on intestinal epithelial cells: activation of signal transduction pathways and perturbations of intestinal absorption and secretionGlycoconj J2000173–417317911201788
   PubMed Web of Science ®Google Scholar
• HannunYABellRMFunctions of sphingolipids and sphingolipid breakdown products in cellular regulationScience198924348905005072643164
   PubMed Web of Science ®Google Scholar
• OliveraABuckleyNESpiegelSSphingomyelinase and cell-permeable ceramide analogs stimulate cellular proliferation in quiescent Swiss 3T3 fibroblastsJ Biol Chem19922673626121261271464623
   PubMed Web of Science ®Google Scholar
• BoydRSJukes-JonesRWalewskaRBrownDDyerMJCainKProtein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphomaMol Cell Proteomics2009871501151519346216
   PubMed Web of Science ®Google Scholar
• Meyer zum BüschenfeldeCFeuerstackeYGötzeKSScholzeKPeschelCGM1 expression of non-Hodgkin’s lymphoma determines susceptibility to rituximab treatmentCancer Res200868135414542218593944
   PubMed Web of Science ®Google Scholar
• DaeflerSKruegerGRLack of dynamic lipid changes after binding of interleukin 2 in chronic lymphatic leukemia lymphocytes indicates defective transmembrane signalingAnticancer Res1989937437482788388
   PubMed Web of Science ®Google Scholar
• DaeflerSKruegerGRExpression of proliferation and differentiation antigens in response to modulation of membrane fluidity in chronic lymphocytic leukemia lymphocytesAnticancer Res1989925015062751273
   PubMed Web of Science ®Google Scholar
• Gouaze-AnderssonVCabotMCGlycosphingolipids and drug resistanceBiochim Biophys Acta20061758122096210317010304
   PubMed Web of Science ®Google Scholar
• ConsoliUSantonocitoAStagnoFMultidrug resistance mechanisms in chronic lymphocytic leukaemiaBr J Haematol2002116477478011886380
   PubMed Web of Science ®Google Scholar
• JamroziakKSmolewskiPCebulaBSzmigielska-KaplonADarzynkiewiczZRobakTRelation of P-glycoprotein expression with spontaneous in vitro apoptosis in B-cell chronic lymphocytic leukemiaNeoplasma200451318118715254670
   PubMed Web of Science ®Google Scholar
• GerrardGButtersTDGaneshaguruKMehtaABGlucosylceramide synthase inhibitors sensitize CLL cells to cytotoxic agents without reversing P-gp functional activityEur J Pharmacol20096091–3343919285492
   PubMed Web of Science ®Google Scholar
• MalisanFTestiRGD3 ganglioside and apoptosisBiochim Biophys Acta200215852–317918712531552
   PubMed Web of Science ®Google Scholar
• Flores-BorjaFKabouridisPSJuryECIsenbergDAMageedRAAltered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosusArthritis Rheum200756129130217195233
   PubMed Web of Science ®Google Scholar
• Flores-BorjaFKabouridisPSJuryECIsenbergDAMageedRADecreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosusArthritis Rheum200552123955396516320343
   PubMed Web of Science ®Google Scholar
• YanagiSSugawaraHKurosakiMSabeHYamamuraHKurosakiTCD45 modulates phosphorylation of both autophosphorylation and negative regulatory tyrosines of Lyn in B cellsJ Biol Chem19962714830487304928940015
   PubMed Web of Science ®Google Scholar
• ClatworthyMRWillcocksLUrbanBSystemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malariaProc Natl Acad Sci U S A2007104177169717417435165
   PubMed Web of Science ®Google Scholar
• KonoHKyogokuCSuzukiTFcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signalingHum Mol Genet200514192881289216115811
   PubMed Web of Science ®Google Scholar
• CoiffierBLepretreSPedersenLMSafety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1–2 studyBlood20081111094110018003886
   PubMed Web of Science ®Google Scholar
• GoldenbergDMRossiEASteinRProperties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibodyBlood200911351062107018941114
   PubMed Web of Science ®Google Scholar
• DuJWangHZhongCCrystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptideMol Immunol2008452861286818346788
   PubMed Web of Science ®Google Scholar
• RobakTGA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignanciesCurr Opin Investig Drugs2009106588596
   PubMed Web of Science ®Google Scholar
• De RomeufCDutertreCALe Garff-TavernierMChronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16Br J Haematol2008140663564318302712
   PubMed Web of Science ®Google Scholar
• LiMYanZHanWZhangYMimotope vaccination for epitopespecific induction of anti-CD20 antibodiesCell Immunol2006239213614316814270
   PubMed Web of Science ®Google Scholar
• JainNWierdaWFerrajoliAA phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemiaCancer2009115194533453919637351
   PubMed Web of Science ®Google Scholar
• CraggMSWalsheCAIvanovAOGlennieMJThe biology of CD20 and its potential as a target for mAb therapyCurr Dir Autoimmun2005814017415564720
   PubMedGoogle Scholar
• BornsteinGGQuévaCTabriziMDevelopment of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignanciesInvest New Drugs2009
   Web of Science ®Google Scholar
• LiBShiSQianWDevelopment of novel tetravalent anti-CD20 antibodies with potent antitumor activityCancer Res2008682400240818381448
   PubMed Web of Science ®Google Scholar
• RossiEAGoldenbergDMCardilloTMSteinRWangYChangCHNovel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeuticsCancer Res2008688384839218922911
   PubMed Web of Science ®Google Scholar